TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY™ (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom of VVA, due to Menopause

TherapeuticsMD Announces FDA Approval of TX-004HR: IMVEXXY™ (estradiol vaginal inserts), the Lowest Dose Vaginal Estrogen Product Approved for the Treatment of Moderate to Severe Dyspareunia, a Symptom of VVA, due to Menopause

May 30, 2018 -IMVEXXY’s applicator-free self-administration was developed with the woman in mind- -TherapeuticsMD will host a conference call at 8:00 AM EDT today- BOCA RATON, Fla., May 30, 2018 /PRNewswire/ — TherapeuticsMD, Inc. (NASDAQ: TXMD), an innovative women’s healthcare company, today announced that the United